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ABSTRACT
Background: The pattern and role of microglial activa-
tion in multiple system atrophy is largely unclear. The
objective of this study was to use [11C](R)-PK11195
PET to determine the extent and correlation of activated
microglia with clinical parameters in MSA patients.
Methods: Fourteen patients with the parkinsonian phe-
notype of MSA (MSA-P) with a mean disease duration of
2.9 years (range 2-5 years) were examined with [11C](R)-
PK11195 PET and compared with 10 healthy controls.
Results: Patients with the parkinsonian phenotype of
MSA showed a significant (P ≤ 0.01) mean increase in
binding potentials compared with healthy controls in the
caudate nucleus, putamen, pallidum, precentral gyrus,
orbitofrontal cortex, presubgenual anterior cingulate cor-
tex, and the superior parietal gyrus. No correlations
between binding potentials and clinical parameters were
found.
Conclusions: In early clinical stages of the parkinso-
nian phenotype of MSA, there is widespread microglial
activation as a marker of neuroinflammatory changes
without correlation to clinical parameters in our patient
population. © 2019 The Authors. Movement Disorders
published by Wiley Periodicals, Inc. on behalf of Inter-
national Parkinson and Movement Disorder Society.
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Multiple system atrophy (MSA) is a sporadically
occurring, adult-onset progressive neurodegenerative
disease and presents clinically with variable combina-
tions of marked autonomic insufficiency combined with
a progressive akinetic-rigid syndrome and/or cerebellar
dysfunction.1,2 The parkinsonian phenotype of MSA
(MSA-P) exhibits predominant parkinsonism, whereas
MSA-C has predominant cerebellar signs.
Histopathological findings in MSA show neuronal loss
mainly in the nigrostriatal and olivopontocerebellar path-
ways, with α-synuclein positive glial cytoplasmic inclu-
sions3 associated with reactive astrocytes and activated
microglia.4-6 α-Synuclein aggregates are released from
degenerating neurons, inducing neuroinflammation in the
form of glial activation that results in cell loss and the for-
mation of further aggregates and thus potentiates its neuro-
degenerating effect.5 Although the exact role of activated
microglia in MSA and other neurodegenerative diseases is
still a matter of discussion, there is evidence that microglia,
once activated, continue to promote disease progression.
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Neuropathological findings demonstrate that microglial
activation parallels system degeneration inMSA.7
Microglia are the resident immunocompetent cells of
the CNS.8 They respond to a variety of pathological
stimuli by developing phagic properties and express
immunologically relevant molecules.9 As these cells react
before signs of tissue damage are apparent, they provide
an early marker of active disease. One of the molecules
selectively expressed by activated microglia is the mito-
chondrial translocator protein 18-kDa TSPO.10 In lesions
with an intact blood-brain barrier, activated microglia
are the primary source of TSPO expression. (R)-
PK11195 (1-[2-chlorophenyl]-N-methyl-N-[1-methylpro-
pyl]-3-isoquinoline carboxamide) is a selective ligand for
TSPO and, when labeled with [11C], can be used as a
PET tracer.11
In a pilot study in patients with MSA using [11C](R)-
PK11195 PET, we previously demonstrated increased
microglial activation in the dorsolateral prefrontal cor-
tex, putamen, pallidum, substantia nigra (SN) and pons
in 5 patients with MSA.12
The aim of our present study was to assess the quan-
tity and distribution of microglial activation in a large
MSA patient cohort using a high-resolution, high-
sensitivity PET camera and to correlate the extent of
microglial activation with clinical parameters.
Methods
Fourteen patients (7 female, 7 male; mean age,
58 years; range 45-73 years) with MSA-P according
to consensus criteria1 were recruited for [11C](R)-
PK11195 PET. Mean disease duration (from the onset
of first motor symptoms) was 2.9 years (range 2 to
5 years). For clinical details, see Table 1. Ten healthy
controls (HCs; 4 female, 6 male, mean age, 59 years;
range 38-70 years) also had [11C](R)-PK11195 PET.
None of the HCs reported any relevant medical history,
and all HCs had a normal neurologic examination.
Ethical approval and permission were given by the
Hammersmith Hospitals Trust Ethics Committee and
the Administration of Radioactive Substances Advisory
Committee of the UK Department of Health. Informed
written consent was obtained from all study partici-
pants prior to enrollment. All procedures were con-
ducted according to the Declaration of Helsinki.
MRI
Volumetric T1-weighted MR images were acquired
for coregistration with PET to define anatomical
regions of interest using a 1.0 T Picker HPQ scanner
(Picker, Cleveland, OH).
[11C](R)-PK11195 PET
Participants underwent 3-dimensional [11C](R)-PK11195
PET using an ECAT EXACT HR++ (CTI/Siemens 966)
camera located in the Cyclotron Building at Hammersmith
Hospital, London, UK, with an axial field of view of
23.4 cm. The tomograph has a spatial resolution of
4.8  0.2 mm FWHM (transaxial, 1 cm off axis) and
5.6  0.5 mm (axial, on axis) after image reconstruction.13
Scanning procedures were performed according to previ-
ously established protocols (please refer to reference 14
and online supplement). Binding potential (BP), a
measure of specific binding of the tracer (Bmax/Kd —
available concentration of binding sites/receptor
TABLE 1. Clinical and demographic data of the MSA-P cohort
Patient
number Age
Disease
duration UPDRS III H + Y S + E Autonomic Cerebellar Pyramidal
L-Dopa
response MSA-P
1 45 2 28 2 100 OH None yes No Possible
2 54 5 52 4 40 OH, urinary urgency None None Only initially Probable
3 51 4 31 3 80 urinary frequency and urgency None None Partial Possible
4 53 2 28 2,5 90 Urinary incontinence, ED None None No Probable
5 64 4 44 3 70 Urinary incontinence None Yes Partial Possible
6 59 2 42 4 50 OH, urinary incontinence None None Poor Probable
7 59 3 41 3 70 Marginal OH Slight action
tremor
Yes Poor Possible
8 73 4 31 3 40 OH None Yes Only initially Probable
9 69 2.5 13 2,5 80 ED, urinary urgency, OH None None Partial Probable
10 47 2 14 2 80 ED, OH None None No Probable
11 57 2.5 31 2,5 70 Urinary frequency and urgency, OH None None No Probable
12 47 3 45 4 40 Urinary incontinence, OH None None Poor Probable
13 63 2 30 2,5 70 ED, urinary incontinence, OH None Yes Poor Probable
14 69 3 30 2,5 80 ED None None No Possible
ED, erectile dysfunction.
Overview of clinical patient data including age and disease duration at study participation in years, UPDRS III, Hoehn and Yahr stage (H + Y), and Schwab and
England scale (S + E). Orthostatic hypotension (OH) is defined by a reduction of systolic blood pressure by at least 30 mm Hg or of diastolic blood pressure by at
least 15 mm Hg within 3 minutes of standing from the recumbent position.
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dissociation constant), was calculated at a voxel level
using a simplified reference tissue model.15 For details,
see reference 16 and online supplement.
Image Analysis
Parametric BP images were coregistered to the
patients’ MRIs (see Fig. 1 in the online supplement).
Volumes of interest (VOIs) were outlined on the MRI
using a probabilistic atlas17 and applied to the corre-
sponding BP maps using Analyze software.18 We
defined the SN on MRI slices where clearly visible, but
as its volume is small compared with PET resolution,
anatomical definition was imprecise when coregistering
the BP map to the MRI. To account for this inaccuracy,
we use the term area of SN.
Mann-Whitney U tests performed with SPSS
23 (SPSS Inc., Chicago, IL) were used to interrogate
the presence of significant differences in mean BP
values between groups, and a Z value was calculated
for each VOI. Seven VOIs that were reported to be
affected in MSA by previous studies (brain stem
[includes the pons and medulla oblongata], cerebel-
lum, caudate nucleus, putamen, pallidum, thalamus,
and area of SN) were selected. Results were corrected
for multiple comparisons using p-plot on an α level of
0.05 (Hochberg correction).19
Data Availability
The data sets generated and/or analyzed during the
current study are available from the corresponding
author on reasonable request.
Results
[11C](R)-PK11195 PET
A significant increase in microglial activation in MSA-P
patients compared with HCs (Fig. 1) was seen in the puta-
men (P = 0.001), caudate nucleus (P = 0.002), pallidum
FIG. 1. Comparison of binding potential (BP) values of MSA-P patients and HCs. [11C](R)-PK11195 BP of MSA-P patients in the 7 selected VOIs and
selected cortical VOIs (mean of left and right, if given). Horizontal bars indicate mean and standard deviation. *P < 0.01, **P ≤ 0.001.
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(P = 0.002), precentral gyrus (P = 0.004), orbitofrontal
cortex (P = 0.006), presubgenual anterior cingulate cortex
(P = 0.006), and superior parietal gyrus (P = 0.007). The
other VOIs did not show a significant difference between
MSA-P patients and HCs. Comparison of BP between
groups looking at the whole brain (P = 0.013), the parie-
tal lobe (P = 0.016), and the frontal lobe (P = 0.022)
revealed a trend toward an increase in BP in MSA-P
patients but did not reach statistical significance (p-
plot, α = 0.05).
Correlation BP Clinical Parameters
Spearman correlation between BP in the selected
VOIs and the clinical parameters age and disease dura-
tion at study participation, sum of the motor part (III)
of the UPDRS, Hoehn and Yahr stage, and Schwab and
England scale did not show significant results (P ≤ 0.05
was considered significant).
Discussion
Neuroinflammation is a crucial part of the neuropatho-
logical changes in MSA,7 and [11C](R)-PK11195 PET
allows detection of the location and extent of activated
microglia in vivo. In our study, [11C](R)-PK11195 PET in
patients with MSA-P detected increased signals in regions
known to be targeted by the disease: the striatum and palli-
dum. In addition, frontal and parietal regions also dis-
played increased BP. Interestingly, there was a trend
toward an increase in BP on a whole-brain level and in the
frontal and parietal lobes. The failure to find a significant
BP increase in the SN is in contrast to our earlier findings.15
However, 12 of our 14 patients showed an increase in this
region compared with the mean BP value of HCs in at least
1 SN. Also, the patients in the previous study had longer
mean disease duration than in our present study (68 versus
35 months) and were clinically more severely affected.
Although the changes in BP values in the cerebellums
of MSA patients were not statistically significant when
compared with those in the HCs, a number of patients
showed raised values. This is of particular interest, as
all our patients were classified as MSA-P and only 1 of
them had a slight tremor. Potentially, the raises in [11C]
(R)-PK11195 binding indicate a “preclinical” change.
Studies in other neurological diseases have shown that
microglial activation can precede clinical manifesta-
tions. Asymptomatic gene carriers have shown
increased striatal and cortical BP in Huntington’s dis-
ease.20 Patients with idiopathic rapid eye movement
sleep behavior disorder showed an increase in BP in the
left SN along with a decrease in F-dopa uptake in the
bilateral putamen compared with HCs.21 As most cases
are converting to α-synucleinopathies, these findings
support the role of microglia as an early component of
neurodegenerative disorders that could be a potential
therapeutic target.
Our patients were clinically at an early stage of the
disease, and we did not find a correlation between
regional BP values and clinical severity. Most had a
diagnosis of probable MSA-P but showed some clinical
heterogeneity. There was high intersubject variability
for regional BP values, a phenomenon that has been
observed in other neurodegenerative disorders that have
been examined with TSPO PET tracers. The high vari-
ability of microglial activation is also reflected in PET
studies of idiopathic Parkinson’s disease, with some
authors finding a correlation with clinical phenotype,
but others failing to do so.22 Because of the lack of
TSPO studies in MSA, we can only assume at this stage
that the clinical phenotype and severity will not be a
simple linear function of the amount and localization of
microglial activation. Overall, microglial activation
appears to happen early in neurological diseases, and
the mutual relationship between neurodegeneration and
neuroinflammation is complex. Ishizawa and colleagues
suggest a distinction in the course of microglial activa-
tion between gray and white matter. They hypothesize
that the amount of microglial activation in MSA is
reduced with increasing severity of tissue injury in
white- but not in gray-matter areas, where such correla-
tions could not be shown.6 Also, although some
authors assume that microglial activation is part of
pathogenesis, it might also be that these cells play a
protective role initially, as has been postulated for
patients with early-stage Alzheimer’s disease.23,24
To further elucidate the complex interaction between
microglial activation and clinical phenotype and pro-
gression in MSA and other neurodegenerative disor-
ders, longitudinal combined clinical and imaging
studies are needed that also investigate other aspects of
microglial activation apart from TSPO expression.25
When interpreting our results, it is important to real-
ize that TSPO expression is only one part of the much
more complex phenomenon of microglial activation.
We currently do not have in vivo imaging methods
available that allow distinguishing between different
types of activated micro- and astroglia. In our study,
we used [11C](R)-PK11195 as a marker of TSPO rather
than one of the second-generation TSPO PET tracers.
[11C](R)-PK11195 is the best characterized TSPO tracer
and has enabled us to compare our results with those
of previous studies of microglial activation in α-synu-
cleinopathies. Also, its binding affinity is not influenced
by the TSPO polymorphism. However, [11C](R)-
PK11195 has a lower specific-to-background signal
ratio than newer microglial tracers, which might lead to
underestimation of the extent of microglial activation.26
We provide evidence that microglial activation is an
important feature of the pathological changes in MSA.
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Decoding the role of neuroinflammation in the patho-
physiology of neurodegenerative diseases is a crucial
step toward possible therapeutic strategies.
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